Transaction and Due Diligence
-
- As the intellectual property legal advisor of Keymed Biosciences Inc. (stock code: 2162. HK), provided FTO and intellectual property legal opinions for its listing on the main board of the Stock Exchange of Hong Kong Ltd. (SEHK);
- As the intellectual property legal advisor of Shukun (Beijing) Network Technology Co., Ltd., provided intellectual property legal opinions for its listing on the main board of the Stock Exchange of Hong Kong Ltd. (SEHK);
- As the intellectual property legal advisor of Shenzhen Edge Medical Co., Ltd., provided FTO and intellectual property legal opinions for its listing on the main board of the Stock Exchange of Hong Kong Ltd. (SEHK);
- Provided full legal services for the intellectual property securitization project, Capital Securities-Hubei Leasing Hubei Province Intangible Assets 1-N Asset Support Special Plan as an intellectual property legal advisor, and provided legal advice for policy formulation and the formulation of standards for selected enterprises from the early stage of legal argumentation to the improvement of the intellectual property secondary licensing transaction model;
- Beijing Heartwarming Biotechnology Research Institute Co., Ltd. entered strategic cooperation with the China Center of Industrial Culture Collection (CICC). M&T, as the intellectual property legal advisor of CICC, provided full legal services for this strategic cooperation;
- GenFleet Therapeutics and Innovent Biologics announced a global strategic collaboration on GFH925 (a small molecule inhibitor of KRAS G12C). The Intellectual Property on Therapeutics Working Group of M&T represented GenFleet Therapeutics to provide the whole process of intellectual property services for this transaction;
- Represented Sequoia Capital in conducting patent due diligence (FTO, etc.) on several pharmaceuticals and medical devices in China, including LP Pharma, Pumice, Biotheus, AccuMedical, Neuracle, Edge Medical, Yuanhua Technology, ET Healthcare, etc.;
- Represented IDG Capital in conducting patent due diligence (FTO, etc.) on Gensciences, Lychix, etc;
- Represented Citic Securities Investment Co., Ltd. in conducting patent due diligence (FTO, etc.) on DAC BIOTECHNOLOGY;
- Represented CITIC Healthcare in conducting patent due diligence (FTO, etc.) on a surgical robot company;
- Represented Shanghai Greenwoods Capital in conducting patent due diligence (FTO, etc.) on Stemirna Therapeutics;
- Represented Dalton Venture in conducting patent due diligence (FTO, etc.) on several medical devices in China, including ShineYo Medical, Chinabridge Medical, etc.;
- Represented Riverhead Capital in conducting patent due diligence (FTO, etc.) on medical device enterprises (biochips) and innovative drug enterprises (small molecule drugs);
- Represented LC Ventures in conducting patent due diligence (FTO, etc.) on Immunophage;
- Represented Legend Capital in conducting patent due diligence (FTO, etc.) on Lychix (biochips);
- Represented Advantech Capital in conducting patent due diligence (FTO, etc.) on a cardiovascular medical device enterprise;
- Provided patent services such as licensing prospect analysis, patent stability analysis, FTO analysis, and others of small molecule drugs and antibody drugs for Livzon Pharmaceutical;
- Represented Korea Investment Partners (KIP) in analyzing the prospects for patent licensing and the risk of product infringement by Maxvax Biology;
- Participated in the popularization and promotion of patent analysis in biological liquid fuel, which is the subject of China National Intellectual Property Administration;
- Participated in the research literature search in biotechnology, which is the subject of China National Intellectual Property Administration;
- Participated in Criteria for Creative Review of Specific Topics in Biotechnology, which is the subject of China National Intellectual Property Administration.